PATENT Customer No. 22,852 Attorney Docket No. 09963,0008

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n re Application of: BARLAAM (AS AMENDED)	) ) Group Art Unit: 1624
Application No.: 10/571,991	) Examiner: WILLIS, Douglas M
Filed: March 15, 2006	)
For: QUINAZOLINE DERIVATIVES	) Confirmation No.: 5523
:	) )

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## Third Supplemental Information Disclosure Statement Under 37 C.F.R. § 1.97(c)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

A copy of non-patent literature documents numbers 18 and 19 are attached. A copy of non-patent literature documents numbers 1-17 are of record, as they were submitted as attachments with the Submission under 37 C.F.R. § 1.114 filed April 6, 2009.

Attorney Docket No. 09963.0008

Application No. 10/571.991

Applicants respectfully request that the Examiner consider the listed documents

and indicate that they were considered by making appropriate notations on the attached

form.

This submission does not represent that a search has been made or that no

better art exists and does not constitute an admission that each or all of the listed

documents are material or constitute "prior art." If the Examiner applies any of the

documents as prior art against any claim in the application and Applicants determine

that the cited documents do not constitute "prior art" under United States law.

Applicants reserve the right to present to the Office the relevant facts and law regarding

the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the

patentability of the disclosed invention over the listed documents, should one or more of

the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please

charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW GARRETT & DUNNER, L.L.P.

Jill MacAlpine, Reg. No. 60, 475

Dated: June 23, 2009

Jill MacAlpin for

> Thomas L. Irving Reg. No. 28,619

(202) 408-4082